首页>投融资
Carmot Therapeutics
收并购
Carmot Therapeutics is a pharmaceutical company pioneering a transformative drug discovery approach, Chemotype Evolution, to identify superior therapeutics for human diseases.By January 2018, the company had relocated its headquarters to a new facility in Berkeley, CA, and maintained a research site in Mission Bay, San Francisco.In February 2010, Carmot Therapeutics signed an exclusive license agreement to apply Sunesis Pharmaceuticals' Fragment-Based Lead Discovery (FBLD) technology (Chemotype Evolution) for identifying drug candidates in therapy areas that include inflammatory, metabolic and neurodegenerative diseases. Sunesis would retain rights to the technology for use in its future internal discoveries. Financial terms were undisclosed.In July 2011, Carmot Therapeutics was awarded a grant from The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for the discovery of FABP type 4 and 5 small molecule inhibitors. The studies could lead to therapeutics for obe
基本信息
-
公司全称Carmot Therapeutics Inc
-
类型代谢性疾病和癌症新药开发商
-
产业领域药品研发/制造、生物药
-
公司人数15人以下
-
地址740 Heinz Avenue BERKELEY CALIFORNIA 94710; US; Telephone: +18884024674;
-
联系电话5105279251
-
邮箱info@carmot.us
-
成立时间2008-01-01
投融资
-
2024-01-29收并购未透露Roche
-
2023-05-25E轮1.5亿美元Deep Track CapitalFranklin Templeton InvestmentsWillett Advisors LLCRA CapitalMillennium5AM VenturesThe Column GroupFrazier Lifesciences Acquisition CorpJanus Henderson InvestorsVenrock Capital
-
2022-07-26D轮1.6亿美元Deep Track CapitalWillett Advisors LLCHorizons VenturesRA CapitalThe Column Group
-
2020-10-02C轮4700万美元AmgenHorizons VenturesThe Column Group
-
2018-01-17B轮1500万美元Horizons VenturesThe Column Group
-
2010-04-12A轮未透露The Column Group
- 加载更多
相关投融资企业
D轮
AgomAb是一种开创性的治疗方法，可以调节再生途径来实现组织结构修复和功能器官恢复。我们不断增长的高特异性单克隆抗体管道，旨在治疗一系列急性和慢性疾病，包括炎症、代谢和纤维化过程。通过将新的科学见解与强大的发展专业知识相结合，我们正在建立一家公司，引导真正再生药物的出现。
股权融资
上海药明海德生物科技有限公司是由海利生物（股票代码：603718.SH）与药明生物（WuXi Biologics, 2269.HK）共同成立的合资企业，并提供人用疫苗从概念到商业化生产全过程的发现、开发及生产“端到端”服务及解决方案平台，主要从事人用疫苗（包括癌症疫苗）合同定制研发生产（CDMO）业务，致力于打造全球疫苗行业领先的一体化能力和技术平台。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息